Related Experiment Videos
Characteristics of SonoVuetrade mark
Echocardiography (Mount Kisco, N.Y.)
|February 15, 2001
Summary
SonoVue, a novel ultrasound contrast agent, utilizes stabilized microbubbles containing sulfur hexafluoride (SF6) for enhanced medical imaging. This agent demonstrates excellent safety and efficacy in improving ultrasound signal for cardiac and vascular assessments.
Area of Science:
- Medical Imaging
- Ultrasound Technology
- Pharmacology
Background:
- Ultrasound imaging has advanced significantly, with contrast agents offering new diagnostic possibilities.
- SonoVue is a new echocontrast agent composed of microbubbles stabilized by phospholipids and containing sulfur hexafluoride (SF6).
Purpose of the Study:
- To evaluate the characteristics and performance of SonoVue as an ultrasound contrast agent.
- To assess the safety and efficacy of SonoVue for cardiac and extracardiac vascular imaging.
Main Methods:
- Characterization of SonoVue microbubbles (concentration, size distribution).
- Assessment of SF6 pharmacokinetics in human volunteers following intravenous administration.
- Evaluation of echogenicity and backscatter properties.
- Safety studies in animals and humans.
Main Results:
- SonoVue exhibits high microbubble concentration (100-500 million/ml) and favorable size distribution (mean 2.5 µm, >90% <8 µm).
- SF6 confers resistance to pressure changes, crucial for cardiac and pulmonary circulation.
- Peak backscatter observed at approximately 3 MHz.
- Pharmacokinetics in humans: distribution half-life ~1 min, elimination half-life ~6 min; >80% SF6 exhaled within 11 min.
- Demonstrated outstanding safety profile and effective ultrasound signal enhancement.
Conclusions:
- SonoVue is a safe and effective second-generation ultrasound contrast agent.
- It significantly enhances ultrasound signal for evaluating cardiac function and extracardiac abnormalities.
- Its properties make it suitable for assessing myocardial perfusion and microcirculatory disorders.